http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0130338-A8

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24a224fe3dfeba8d1051e4948c62b855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8ec35c2549b36b67e202b24d68d7193
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52c300047cb7ad784edea9892e65ec6f
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-265
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-265
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C43-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167
filingDate 2000-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e43172d0acc343a3825bac29d2a15f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78f901402c90b519e675779216085dcf
publicationDate 2002-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-0130338-A8
titleOfInvention 6-methoxy-2-naphthylacetic acid prodrugs for treating inflammation
abstract The present invention provides therapeutically effective amounts of 6MNA prodrugs. The pharmaceutical composition comprises (1), wherein R is H or COR", wherein R" is selected from the group consisting of C1 to C6 alkyl, (CH2)m O(CH2)n, (CH2)m(OC2H4)p O(CH2)n, (CH2)m(OC2H4)p, (OCH2H4)p ONO2 and (OCH2H4)p O(CH2)n wherein m is an integer from 2 to 4, and n and p are integers from 1 to 4. Alternatively, R is a therapeutic moiety.
priorityDate 1999-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID32176
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419576264
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393737

Total number of triples: 35.